Attached files
| file | filename |
|---|---|
| EX-21.1 - EX-21.1 - EyePoint Pharmaceuticals, Inc. | eypt-ex211_11.htm |
| 10-K - 10-K - EyePoint Pharmaceuticals, Inc. | eypt-10k_20191231.htm |
| EX-32.1 - EX-32.1 - EyePoint Pharmaceuticals, Inc. | eypt-ex321_6.htm |
| EX-32.2 - EX-32.2 - EyePoint Pharmaceuticals, Inc. | eypt-ex322_7.htm |
| EX-31.2 - EX-31.2 - EyePoint Pharmaceuticals, Inc. | eypt-ex312_9.htm |
| EX-4.5 - EX-4.5 - EyePoint Pharmaceuticals, Inc. | eypt-ex45_389.htm |
| EX-10.32 - EX-10.32 - EyePoint Pharmaceuticals, Inc. | eypt-ex1032_519.htm |
| EX-31.1 - EX-31.1 - EyePoint Pharmaceuticals, Inc. | eypt-ex311_8.htm |
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in Registration Statement Nos. 333-152146, 333-163208 and 333-216166, 333-227525 and 333-233137 on Form S-8 and Registration Nos. 333-226341 and 333-228581 on Form S-3 of our reports dated March 13, 2020, relating to the financial statements of EyePoint Pharmaceuticals, Inc. and subsidiaries (which report expresses an unqualified opinion and includes explanatory paragraphs relating to a change in accounting principle and going concern), and the effectiveness of Eyepoint Pharmaceutical Inc. and subsidiaries’ internal control over financial reporting, appearing in this Annual Report on Form 10-K for the year ended December 31, 2019.
/s/ Deloitte & Touche LLP
Boston, Massachusetts
March 13, 2020